Resource Type

Journal Article 108

Conference Videos 1

Year

2023 9

2022 13

2021 13

2020 6

2019 10

2018 8

2017 6

2016 4

2015 5

2014 6

2013 3

2012 3

2011 2

2010 1

2009 3

2008 4

2007 2

2006 2

2005 1

1999 1

open ︾

Keywords

immunotherapy 7

COVID-19 6

SARS-CoV-2 5

immune checkpoint inhibitor 4

monoclonal antibody 4

PD-L1 3

lung cancer 3

Antibody response 2

Colorectal cancer 2

Coronavirus disease 2019 2

DNA damage 2

Immune regulation 2

Monoclonal antibody 2

antibody 2

immune escape 2

immune response 2

polyclonal antibody 2

resistance 2

-acetylglucosamine 1

open ︾

Search scope:

排序： Display mode:

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

Yumeng Wang, Guiling Li

Frontiers of Medicine 2019, Volume 13, Issue 4,   Pages 438-450 doi: 10.1007/s11684-018-0674-4

Abstract: recent years, exciting progress has been made in immunotherapies, including the rapid development of immunecheckpoint inhibitors.Checkpoint blockades targeting the PD-1/PD-L1 axis have achieved effective clinical responses with acceptable

Keywords： PD-1     PD-L1     immune checkpoint blockade antibody     immunotherapy     cervical cancer    

HTML PDF Collect

Liver-directed treatment is associated with improved survival and increased response to immune checkpointblockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Frontiers of Medicine   Pages 878-888 doi: 10.1007/s11684-023-0993-y

Abstract: A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included

Keywords： uveal melanoma     liver-directed therapy     immune checkpoint blockade     SIRT     anti-PD-1     anti-CTLA-4    

HTML PDF Collect

Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases

Zhen Xiang, Yingyan Yu

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 24-31 doi: 10.1007/s11684-019-0679-7

Abstract: Immune checkpoint inhibitors are a promising strategy in the treatment of cancer, especially advancedHowever, not all patients are responsive to immune checkpoint inhibitors.of immune checkpoint proteins, and molecular subtypes of cancers.checkpoint blockade in solid tumor treatment, possible mechanisms of drug resistance, strategies ofovercoming resistance, and indications for immune checkpoint inhibitor therapy.

Keywords： immune checkpoint blockade     sensitivity     resistance     data mining    

HTML PDF Collect

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms

Frontiers of Medicine   Pages 805-822 doi: 10.1007/s11684-023-1025-7

Abstract: Immunotherapies based on immune checkpoint blockade (ICB) have significantly improved patient outcomesTo date, immune checkpoint inhibitors (ICIs) of CTLA-4 and PD-1/PD-L1 represent the main class of immunotherapyBlockade of CTLA-4 and PD-1/PD-L1 has shown remarkable efficacy in several specific types of cancers,Recently, numerous studies have revealed that metabolic reprogramming of tumor cells restrains immuneHere, we demonstrate the generalized mechanism of targeting cancer metabolism at three crucial immune

Keywords： CTLA-4     PD-1     PD-L1     immune checkpoint blockade (ICB)     metabolic reprogramming     combined tumor therapeutic    

HTML PDF Collect

Advances on immune-related adverse events associated with immune checkpoint inhibitors

Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 33-42 doi: 10.1007/s11684-019-0735-3

Abstract: Immunotherapy has recently led to a paradigm shift in cancer therapy, in which immune checkpoint inhibitorsnon-specific activation of effector T cells, ICIs are remarkably associated with a substantial risk of immune-related

Keywords： cancer     immunotherapy     immune checkpoint inhibitors     immune-related adverse events     review    

HTML PDF Collect

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Frontiers of Medicine 2018, Volume 12, Issue 2,   Pages 229-235 doi: 10.1007/s11684-017-0581-0

Abstract: MSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immune

Keywords： molecular classification     precision medicine     pembrolizumab     PD-1/PD-L1     MSI-H    

HTML PDF Collect

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 307-321 doi: 10.1007/s11684-022-0927-0

Abstract: The discovery of immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has played an importantcheckpoint inhibitors.Clinical practice has revealed that antibiotics can weaken the therapeutic response to immune checkpointStudies have shown that the gut microbiota is essential for the interaction between immune checkpointThis review focuses on the interactions between immune checkpoint inhibitors and antibiotics, with an

Keywords： tumor immunotherapy     immune checkpoint inhibitor     antibiotics     gut microbiota     drug–drug interaction    

HTML PDF Collect

Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 773-783 doi: 10.1007/s11684-021-0902-1

Abstract: The total number of cancer patients who are eligible for and will benefit from immune checkpoint inhibitorspatients with eligibility and response to ICIs based on the 2015 Chinese cancer statistics and the immunecheckpoint inhibitor clinical practice guideline of the Chinese Society of Clinical Oncology.

Keywords： benefit     China     eligibility     immune checkpoint inhibitor     public health    

HTML PDF Collect

Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 596-609 doi: 10.1007/s11684-021-0868-z

Abstract: Sialic acid binding Ig-like lectin 10 (Siglec10) is a member of innate immune checkpoints that inhibitsthe activation of immune cells through the interaction with its ligand CD24 on tumor cells.

Keywords： innate immune checkpoint     Siglec10     kidney renal clear cell carcinoma    

HTML PDF Collect

Development of oncolytic virotherapy: from genetic modification to combination therapy

Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu

Frontiers of Medicine 2020, Volume 14, Issue 2,   Pages 160-184 doi: 10.1007/s11684-020-0750-4

Abstract: Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and safety have been genetically modified, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

Keywords： immunotherapy     oncolytic virus     genetic modification     immune checkpoint blockade     chimeric antigen receptor    

HTML PDF Collect

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 32-44 doi: 10.1007/s11684-018-0678-0

Abstract: In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overallTherefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies toHere, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpoint

Keywords： immune checkpoint     companion diagnosis     PD-L1     tumor mutation burden     immune score    

HTML PDF Collect

Activation of phagocytosis by immune checkpoint blockade

Chia-Wei Li, Yun-Ju Lai, Jennifer L. Hsu, Mien-Chie Hung

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 473-480 doi: 10.1007/s11684-018-0657-5

Abstract:

Inhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immuneAs more and more immune receptors are found to be expressed on TAMs, the corresponding therapies may

Keywords： CD47     PD-1     PD-L1     immunotherapy     TAM     phagocytosis     macrophage    

HTML PDF Collect

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 105-118 doi: 10.1007/s11684-022-0934-1

Abstract: In this study, OSI induced higher CD47 expression, an important anti-phagocytic immune checkpoint, viaThe combination treatment of OSI and the anti-CD47 antibody exhibited dramatically increasing phagocytosisin HCC827 and NCI-H1975 cells, which highly relied on the antibody-dependent cellular phagocytosis effectMeanwhile, combining the anti-CD47 antibody significantly augmented the anticancer effect of OSI in HCC827Notably, OSI induced the surface exposure of “eat me” signal calreticulin and reduced the expression of immune-inhibitory

Keywords： osimertinib     anti-CD47 antibody     combination strategy     ADCP     EGFR    

HTML PDF Collect

Immunometabolism: a new dimension in immunotherapy resistance

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 585-616 doi: 10.1007/s11684-023-1012-z

Abstract: Immune checkpoint inhibitors (ICIs) have demonstrated unparalleled clinical responses and revolutionizedof metabolic intervention with ICIs to reap synergic benefits and facilitate an adjusted anti-tumor immune

Keywords： immune cell     immunometabolism     metabolic reprogramming     immunotherapy     resistance     tumor microenvironment     immune checkpoint inhibitor    

HTML PDF Collect

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation

Frontiers of Medicine doi: 10.1007/s11684-023-0996-8

Abstract: Here, we discovered that BGB-A445, a non-ligand-competitive agonistic anti-OX40 antibody currently underdose-dependently and significantly depleted regulatory T cells in vitro and in vivo via antibody-dependentdemonstrated robust and dose-dependent antitumor efficacy, whereas the ligand-competitive anti-OX40 antibodyFurthermore, BGB-A445 demonstrated a strong combination antitumor effect with an anti-PD-1 antibody.not block OX40–OX40L interaction in contrast to clinical-stage anti-OX40 antibodies, shows superior immune-stimulating

Keywords： BGB-A445     OX40     agonistic antibody     OX40L noncompetitive    

HTML PDF Collect

Title Author Date Type Operation

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

Yumeng Wang, Guiling Li

Journal Article

Liver-directed treatment is associated with improved survival and increased response to immune checkpointblockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Journal Article

Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases

Zhen Xiang, Yingyan Yu

Journal Article

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms

Journal Article

Advances on immune-related adverse events associated with immune checkpoint inhibitors

Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang

Journal Article

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Journal Article

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Journal Article

Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

Journal Article

Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient

Journal Article

Development of oncolytic virotherapy: from genetic modification to combination therapy

Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu

Journal Article

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Journal Article

Activation of phagocytosis by immune checkpoint blockade

Chia-Wei Li, Yun-Ju Lai, Jennifer L. Hsu, Mien-Chie Hung

Journal Article

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Journal Article

Immunometabolism: a new dimension in immunotherapy resistance

Journal Article

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation

Journal Article